

## RT-LAMP has high accuracy for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs from asymptomatic and symptomatic individuals

\*†Stephen P. Kidd<sup>1,2</sup>, †Daniel Burns<sup>1,3</sup>, Bryony Armson<sup>1,2,4</sup>, Andrew D. Beggs<sup>5</sup>, Emma L. A. Howson<sup>6</sup>, Anthony Williams<sup>7</sup>, Gemma Snell<sup>7</sup>, Emma L. Wise<sup>1,8</sup>, Alice Goring<sup>1</sup>, Zoe Vincent-Mistiaen<sup>9</sup>, Seden Grippon<sup>1</sup>, Jason Sawyer<sup>10</sup>, Claire Cassar<sup>10</sup>, David Cross<sup>10</sup>, Tom Lewis<sup>10</sup>, Scott M. Reid<sup>10</sup>, Samantha Rivers<sup>10</sup>, Joe James<sup>10</sup>, Paul Skinner<sup>10</sup>, Ashley Banyard<sup>10</sup>, Kerrie Davies<sup>11</sup>, Anetta Ptasinaska<sup>5</sup>, Celina Whalley<sup>5</sup>, Charlie Poxon<sup>5</sup>, Andrew Bosworth<sup>5</sup>, Michael Kidd<sup>5,12</sup>, Nicholas Machin<sup>13</sup>, Alex Richter<sup>14</sup>, Jane Burton<sup>15</sup>, Hannah Love<sup>15</sup>, Sarah Fouch<sup>1</sup>, Claire Tillyer<sup>1</sup>, Amy Sowood<sup>1</sup>, Helen Patrick<sup>1</sup>, Nathan Moore<sup>1</sup>, Michael Andreou<sup>16</sup>, Shailen Laxman<sup>16</sup>, Nick Morant<sup>17</sup>, Duncan Clark<sup>17</sup>, Charlotte Walsh<sup>17</sup>, Rebecca Houghton<sup>1</sup>, Joe Parker<sup>18</sup>, Joanne Slater-Jefferies<sup>18</sup>, Ian Brown<sup>10</sup>, Zandra Deans<sup>2</sup>, Deborah Porter<sup>2</sup>, Nicholas J. Cortes<sup>1,9</sup>, Keith M. Godfrey<sup>19,20</sup>, Angela Douglas<sup>2</sup>, Sue L. Hill<sup>2</sup>, Veronica L. Fowler<sup>1,2</sup>

<sup>1</sup>Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and North Hants Hospital, Basingstoke, UK

<sup>2</sup>NHS Test and Trace Programme, Department of Health and Social Care, UK

<sup>3</sup>School of Electronics and Computer Science, University of Southampton, UK

<sup>4</sup>vHive, School of Veterinary Medicine, University of Surrey, Guildford, UK

<sup>5</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>6</sup>The Pirbright Institute, Ash Road, Pirbright, Woking, UK

<sup>7</sup>University of Southampton & Division of Specialist Medicine, University Hospital Southampton, UK

<sup>8</sup>School of Biosciences and Medicine, University of Surrey, Guildford, UK

<sup>9</sup>Gibraltar Health Authority, Gibraltar, UK

<sup>10</sup>Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK

<sup>11</sup>Leeds Teaching Hospitals NHS Trust and University of Leeds, UK

<sup>12</sup>Public Health West Midlands Laboratory, Birmingham, UK

<sup>13</sup>Public Health Laboratory Manchester, Manchester Royal Infirmary, Manchester, UK

<sup>14</sup>Institute of Immunology and Immunotherapy, University of Birmingham, UK

<sup>15</sup>High Containment Microbiology, National Infection Service, Public Health England, Porton Down, UK

<sup>16</sup>OptiSense Limited, Horsham, West Sussex, UK

<sup>17</sup>GeneSys Biotech Limited, Camberley, Surrey, UK

<sup>18</sup>National Biofilms Innovation Centre, University of Southampton, UK

<sup>19</sup>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital, UK

<sup>20</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, UK

\*Corresponding author: - [stephen.kidd@hhft.nhs.uk](mailto:stephen.kidd@hhft.nhs.uk), †Denotes co-first authorship

## Abstract

Previous studies have described RT-LAMP methodology for the rapid detection of SARS-CoV-2 in nasopharyngeal/oropharyngeal swab and saliva samples. Here we describe the validation of an improved simple sample preparation method for Direct SARS-CoV-2 RT-LAMP, removing the need for RNA extraction, using 559 swabs and 86,760 saliva samples from asymptomatic and symptomatic individuals across multiple healthcare settings. Using this improved method we report a diagnostic sensitivity (DSe) of 70.35% (95% CI 63.48-76.60%) on swabs and 84.62% (79.50-88.88%) on saliva, with diagnostic specificity (DSp) 100% (98.98-100.00%) on swabs and 100% (99.72-100.00%) on saliva when compared to RT-qPCR. Analysing samples with RT-qPCR ORF1ab C<sub>T</sub> values of  $\leq 25$  and  $\leq 33$  (high and medium-high viral loads, respectively), we found DSe of 100% (96.34-100%) and 77.78% (70.99-83.62%) for swabs, and 99.01% (94.61-99.97%) and 87.32% (80.71-92.31%) for saliva. We also describe RNA RT-LAMP (on extracted RNA) performed on 12,619 swabs and 12,521 saliva samples to provide updated performance data with DSe and DSp of 95.98% (92.74-98.06%) and 99.99% (99.95-100%) for swabs, and 80.65% (73.54-86.54%) and 99.99% (99.95-100%) for saliva, respectively. We also report on daily samples collected from one individual from symptom onset where both Direct and RNA RT-LAMP detected SARS-CoV-2 in saliva collected on all six days where symptoms were recorded, with RNA RT-LAMP detecting SARS-CoV-2 for an additional further day. The findings from these studies demonstrate that RT-LAMP testing of swabs and saliva is potentially applicable to a variety of use-cases, including frequent, interval-based testing of saliva from asymptomatic individuals via Direct RT-LAMP that may be missed using symptomatic testing alone.

## Key Words

SARS-CoV-2, RT-LAMP, Saliva, Direct assay

## Introduction

Rapid diagnostic testing to identify and isolate symptomatic and asymptomatic individuals potentially transmitting infectious viral pathogens is an essential requirement of any pandemic response. The novel *betacoronavirus*, SARS-CoV-2, initially identified after an outbreak of viral pneumonia in Wuhan, China in December 2019<sup>1</sup>, has rapidly spread throughout the world, causing over 141 million confirmed cases and over 3.1 million deaths<sup>2</sup>, (April, 2021).

Conventional diagnostics for SARS-CoV-2 consist of RNA enrichment followed by reverse-transcriptase quantitative real-time PCR (RT-qPCR) against one or more viral gene targets<sup>3</sup>. However, this methodology requires sample inactivation, RNA extraction and RT-qPCR thermal cycling, meaning that the time from sample-to-result can often be several hours, and requires centralised equipment and personnel trained in Good Laboratory Practice to perform testing.

We have previously shown the utility of reverse-transcriptase loop mediated isothermal amplification (RT-LAMP) for the detection of SARS-CoV-2 both from extracted RNA (RNA RT-LAMP) and directly from nasopharyngeal/oropharyngeal swabs (Direct RT-LAMP)<sup>4</sup>. RT-LAMP utilises a rapid and stable DNA polymerase that amplifies target nucleic acids at a constant temperature. This removes the requirement for conventional thermal cycling allowing RT-LAMP reactions to be performed in shorter reaction times using less sophisticated platforms.

In a study of 196 clinical samples<sup>4</sup>, testing of RNA extracted from nasopharyngeal/oropharyngeal swabs collected into viral transport media (VTM) using RNA RT-LAMP demonstrated a diagnostic sensitivity (DSe) of 97% and a diagnostic specificity (DSp) of 99% in comparison to RT-qPCR of the ORF1ab region of SARS-CoV-2. For Direct RT-LAMP on crude swab samples, the DSe and DSp were 67% and 97%, respectively. When a cycle threshold ( $C_T$ ) cut-off for RT-qPCR of  $< 25$  was considered, reflecting the increased likelihood of detecting viral RNA from active viral replication, the DSe of Direct RT-LAMP increased to 100%<sup>4</sup>.

However, the collection of a swab sample is invasive and during the time of the pandemic there have been considerable shortages in swab supplies. Exploring the use of alternative sample types that are both easy to collect and more of a comfortable from a sampling perspective is desirable particularly when repeat sampling is performed. Saliva presents an ideal bio-fluid that fulfils both these objectives and previous studies have shown that SARS-CoV-2 is readily detectable in such a sample type<sup>5-10</sup>. To improve the diagnostic sensitivity of previously described saliva Direct RT-LAMP<sup>4</sup>, optimisation of saliva preparation for the detection of SARS-CoV-2 was undertaken utilising a cohort of 3100 saliva samples from an asymptomatic population<sup>11</sup> of healthcare workers; where saliva was

diluted 1:1 in Mucolyse™, followed by a 1 in 10 dilution in 10% (w/v) Chelex® 100 Resin ending with a 98°C heat step prior to RT-LAMP which resulted in optimal sensitivity and specificity.

Despite the benefits of this optimisation, the protocol added additional steps and reagents which increased chance for user error and made the automation of the process more challenging. We therefore aimed to investigate a simpler process using a novel reagent, RapiLyze (OptiGene Ltd), which is a sample dilution buffer, followed by a two-minute heat-step. This novel sample preparation method was evaluated in combination with Direct RT-LAMP using samples collected from symptomatic NHS patients and symptomatic and asymptomatic NHS healthcare staff.

## Methods

### Testing sites

The OptiGene Ltd. SARS-CoV-2 RT-LAMP assay was evaluated in nine sites, comprising Basingstoke and North Hampshire Hospital & Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust; University Hospital Southampton; Animal and Plant Health Agency/MRC Lifecourse Epidemiology Unit (University of Southampton); Public Health Lab Manchester/CMFT; Leeds Teaching Hospitals NHS Trust; University Hospitals Birmingham NHS Foundation Trust/Institute of Cancer & Genomic Science University of Birmingham; High Containment Microbiology, National Infection Service, Public Health England, Porton Down and Public Health University Laboratory, Gibraltar Health Authority, Gibraltar, UK.

### Clinical samples

Nasopharyngeal and oropharyngeal swabs were collected from asymptomatic and symptomatic individuals and placed in viral transport media (VTM).

Drooled saliva samples were collected at the start of the day; prior to eating, drinking, teeth brushing, or using a mouthwash. Saliva was transferred into the specimen pot directly or via a clean teaspoon, according to a standardised protocol. Samples from UHB deposited saliva straight into the collection pot.

### RNA extraction

RNA was extracted using a range of different methods available at each participating site:

#### *Maxwell® RSC Viral Total Nucleic Acid Purification Kit*

In a class 1 microbiological safety cabinet (MSC) within a containment level 3 laboratory, 200 µl of sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of Genesig® Easy RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were then inactivated for 10 minutes at room temperature within the MSC and 10 minutes at 56°C on a heat block before automated RNA extraction using a Maxwell® RSC48 Instrument (Promega UK Ltd., Southampton, UK). RNA was eluted in 50 µl of nuclease-free water (NFW).

#### *MagMAX™CORE Nucleic acid 140 purification kit*

10 µl of sample (diluted in 190µl DEPC treated water) was added to 700 µl of prepared lysis solution. Samples were then inactivated for 10 minutes at room temperature within the safety cabinet before automated RNA extraction using a Kingfisher Flex (Thermofisher). RNA was eluted in 90 µl of NFW.

#### *Roche FLOW system*

RNA extraction was carried out on a MagNA Pure 96 (MP96) extraction robot using the MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume kit (Roche) and the Pathogen 200 universal protocol v4.0.

#### *Qiagen QIASymphony*

RNA extraction was carried out using the QIASymphony Virus/Bacteria Mini Kit (Qiagen) by the CellFree200 Default IC protocol with a 60 µl extract elution volume.

### **SARS-CoV-2 Real-Time RT-qPCR**

RNA was analysed using a range of different methods available at each site:

#### *CerTest VIASURE SARS-CoV-2 real time qPCR assay*

Single step RT-qPCR against the *ORF1ab* region and *N1* gene target of SARS-CoV-2 was carried out using the CerTest VIASURE SARS-CoV-2 real time PCR kit (CerTest Biotech SL, Zaragoza, Spain) according to manufacturer's instructions for use (IFU) on either the ThermoFisher QuantStudio 5 or BioMolecular Systems MIC instruments, using 5 µl of extracted RNA per reaction. RNA extracted using the Maxwell® RSC Viral Total Nucleic Acid Purification Kit was analysed using this assay.

#### *COVID-19 genesig® Real-Time qPCR assay*

Single step RT-qPCR against the *ORF1ab* region of SARS-CoV-2 was carried out using the COVID-19 genesig® Real-Time PCR assay real time PCR assay (Primerdesign Ltd, Chandler's Ford, UK) according to manufacturer's instructions for use (IFU) on BioMolecular Systems MIC instruments, using 5 µl of extracted RNA per reaction. RNA extracted using the Maxwell® RSC Viral Total Nucleic Acid Purification Kit was analysed using this assay.

#### *Corman et al. Real-Time qPCR assay*

Single step RT-qPCR against the *E* gene target of SARS-CoV-2 was carried out with the Corman *et al.*<sup>3</sup> primers using the AgPath-ID™ PCR kit (Thermofisher) according to manufacturer's instructions for use (IFU) on an Aria qPCR Cycler (Agilent) and results analysed using the Agilent AriaMX 1.5

software, using 5 µl of extracted RNA per reaction. RNA extracted using the MagMAX™ CORE Nucleic acid purification kit were analysed using this assay.

RT-qPCR was carried out on an Applied Biosystems Fast 7500 PCR thermocycler in standard run mode using the SARS-CoV-2 *E* gene Sarbeco assay using MS2 as an internal extraction control and aliquots of SARS-CoV-2/England/2/2020 as a positive control. The master mix comprised *E*- gene F and R primers and TM-P (400 nM, 400 nM and 200 nM final concentration respectively), MS2 primers and TM probe (20 nM, 20 nM and 40 nM final concentration respectively), 4 x TaqMan® Fast Virus 1-Step Master Mix made up with molecular-grade nuclease free water (Ambion) to a final volume of 15 µl. 5 µl of AVE buffer extract was used as a template and added to the 15 µl mastermix. Cycling conditions were 55°C for 10 min, followed by 94°C for 3 min and 45 cycles of 95°C for 15 s and 58°C for 30 s.

#### *SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay*

Single step RT-qPCR against the *N1* and *N2* gene targets of SARS-CoV-2 was carried out using integrated design technologies kit (IDT; Catalogue number: 10006606) according to manufacturer's instructions for use (IFU) on either a LC480 II or ABI 7500 FAST instrument. RNA extracted on Qiagen QIASymphony and the Roche FLOW system were analysed using this RT-qPCR assay.

#### **RT-LAMP**

RT-LAMP assays were performed using OptiGene Ltd. (Horsham, UK) COVID-19\_RT-LAMP kits, as described previously<sup>4</sup>, with the following modifications. The COVID-19\_RNA RT-LAMP KIT-500 kit was used for RNA RT-LAMP and the COVID-19\_Direct PLUS RT-LAMP KIT-500 was used for Direct RT-LAMP directly on oropharyngeal/nasopharyngeal swabs or saliva samples. The COVID-19\_Direct PLUS RT-LAMP KIT-500 kit also includes a sample preparation buffer, RapiLyze. For RNA RT-LAMP 5 µl of extracted RNA was added to the reaction. For the Direct PLUS RT-LAMP, 50 µl sample (swab VTM or neat saliva) was added to 50 µl RapiLyze, vortexed and placed in a dry heat block pre-heated to 98°C for 2 mins. 5 µl of the treated sample was added to each reaction.

The anneal temperature ( $T_a$ ) that confirmed a positive result for Direct RT-LAMP was modified to 81.5°C and 85.99°C because of the effect of RapiLyze buffer on the reaction.

#### **SARS-CoV-2 viral culture of clinical samples across a $C_T$ range**

For culture 100  $\mu$ l and 100  $\mu$ l of a 1 in 10 dilution of the first 10 samples (with predicted lower  $C_T$  values) and 100  $\mu$ l from the second twenty samples (with higher predicted  $C_T$  values) were added to a 25 cm<sup>2</sup> flasks containing 80% confluent Vero E6 cells and allowed to adsorb for 1 hour. Five ml of Minimum Essential Medium (MEM) (Gibco) + HEPES (Gibco) + 4% foetal calf serum FCS (Sigma) + 1 x antibiotic-antimycotic (Gibco) was added to each flask and incubated for 1 week at 37°C. Two negative control flasks to which 100  $\mu$ l MEM + 4% FCS was added in place of sample, were set up in parallel. Cultures were checked visually for cytopathic effect (cpe). Where cpe was not observed after 1 week, 500  $\mu$ l of supernatant was passed into a fresh flask containing Vero E6 cells for a further two passages. At the beginning and end of each passage 140  $\mu$ l of supernatant was collected for SARS-CoV-2 RT-qPCR as described before.

To determine the sensitivity of isolation method for SARS-CoV-2 from clinical samples, a virus stock titred by plaque assay (HCM/V/53), a P3 working bank grown from SARS-CoV-2 Strain England 2, from Public Health England, was diluted in MEM to give virus dilutions containing 1000 pfu to 0.01 pfu. Virus isolation was performed as above in duplicate. After 72 hours of incubation flasks were checked for cpe, and for those where cpe was observed the supernatant was collected for RT-qPCR. Any flasks not showing cpe after 7 days were passed on to fresh cells and resampled as described above.

### Data analysis

Overall diagnostic sensitivity and specificity (including 95% Clopper-Pearson confidence intervals) were calculated by the aggregation of individual site data for each method (RNA and Direct RT-LAMP) for each sample type (swabs and saliva). To demonstrate the effectiveness of detecting samples with higher viral load, confusion matrices are quoted where the threshold for *positive* sample inclusion varies, i.e., for  $C_T \leq 25$ , only positive samples with  $C_T \leq 25$  are included.

To account for site heterogeneity, a bivariate meta-analysis model is additionally applied at the site level to produce a summary sensitivity and specificity for each method and sample type<sup>12</sup>. Within-study variability for sensitivity  $\rho_{se,i}$  and specificity  $\rho_{sp,i}$  are assumed to follow independent binomial distributions

$$x_{se,i} \sim B(n_{se,i}, \rho_{se,i}), \quad x_{sp,i} \sim B(n_{sp,i}, \rho_{sp,i})$$

where  $x_{se,i}$ ,  $x_{sp,i}$  represent the number testing positive for site  $i$  respectively, and  $n_{se,i}$ ,  $n_{sp,i}$  represent the number testing positive and negative by RT-qPCR for site  $i$  respectively. The between-



study heterogeneity is represented by a bivariate normal distribution for the logit-transformed sensitivity  $\mu_{se,i}$  and specificity  $\mu_{sp,i}$

$$\begin{pmatrix} \mu_{se,i} \\ \mu_{sp,i} \end{pmatrix} \sim N \left( \begin{pmatrix} \mu_{se} \\ \mu_{sp} \end{pmatrix}, \begin{pmatrix} \sigma_{se}^2 & \sigma_{se,sp} \\ \sigma_{se,sp} & \sigma_{sp}^2 \end{pmatrix} \right)$$

where  $\mu_{se}, \mu_{sp}$  represent the expected logit sensitivity and specificity,  $\sigma_{se}^2, \sigma_{sp}^2$  represent the between-study variance in the logit sensitivity and specificity, and  $\sigma_{se,sp}$  represents the covariance between the logit sensitivity and specificity. For Direct RT-LAMP, we fit a univariate normal distribution for the logit-transformed sensitivity only due to the absence of false positives across all sites.

In addition, the sensitivity as a function of viral load was assessed for RNA RT-LAMP and Direct RT-LAMP on both swab and saliva samples. This was performed through the conversion of each sample  $C_T$  value to viral load in gene copies/ml for all sample sets. As the relationship between  $C_T$  value and viral load varied according to the RT-qPCR method used; a dilution series was utilised for each method to standardise these values for two of the four aforementioned RT-qPCR methods (CerTest VIASURE SARS-CoV-2 real time PCR kit, and Corman *et al* RT-qPCR assay *E* gene), which was used for testing 100% of the swab samples, 90% of the saliva samples used for Direct RT-LAMP, and 83% of the saliva samples used for RNA RT-LAMP. The logarithm of the viral load was then fitted to the  $C_T$  values for both methods using linear regression followed by converting the  $C_T$  values to viral load based on which method had been used to evaluate the samples. For the remaining samples ( $n=56$ ) that utilised one of the other two RT-qPCR methods for which viral load was not standardised against a  $C_T$  value, the conversion derived from the CerTest VIASURE SARS-CoV-2 real time PCR kit dilution series was applied, the assumption that the *N* gene  $C_T$  values are the most similar<sup>13-15</sup>.

For the CerTest VIASURE SARS-CoV-2 real time PCR kit, the following relationship between log viral load and  $C_T$  value was applied:

$$\log_{10} V = (45.257 - C_T) / 3.523$$

and similarly, for the Corman *et al* RT-qPCR assay:

$$\log_{10} V = (45.806 - C_T) / 3.717$$

where  $V$  represents the viral load in copies/ml.

Viral load was grouped according to the following categories (in copies/ml):  $<10^3$ ,  $10^3$ - $10^4$ ,  $10^4$ - $10^5$ ,  $10^5$ - $10^6$ ,  $10^6$ - $10^7$  and  $>10^7$  then the diagnostic sensitivity was calculated according to viral load group with associated Clopper-Pearson 95% confidence intervals.

The site meta-analysis was produced using R 3.5.3. Confusion matrices, sensitivity, specificity, sensitivity as a function of viral load calculations, and the production of scatter graphs showing the relationship between RT-LAMP results and  $C_T$  were performed using Python 3.8.6.

## Results

### RNA RT-LAMP

VTM from 12,619 naso/oropharyngeal swabs were assayed. 265 swab samples were from known symptomatic individuals and 2073 swab samples were from known asymptomatic individuals. The clinical status of the remaining samples (n= 10,281) was unknown.

12,521 neat saliva samples were assayed, none of which were from known symptomatic individuals. 12,365 of these samples were from known asymptomatic individuals. The clinical status of the remaining saliva samples (n= 156) was unknown.

### Direct RT-LAMP

VTM from 559 naso/oropharyngeal swabs were assayed. 170 swab samples were from known symptomatic individuals and 310 samples were from known asymptomatic individuals and the clinical status of the remaining swab samples (n= 79) was unknown.

86,760 neat saliva samples were assayed. 93 samples were from known symptomatic individuals and 86,593 samples were from known asymptomatic individuals. The clinical status of the remaining samples (n= 74) was unknown. In addition, 10 separate longitudinal daily saliva samples were provided from one individual as a time course from development of symptoms to three days post resolution of symptoms.

### RNA RT-LAMP on naso/oropharyngeal swabs

A total of 12,619 swab samples were assayed by RNA RT-LAMP, of which 254 were RT-qPCR positive and 12,365 were RT-qPCR negative. RNA RT-LAMP detected 244 of the 254 positives (Figure 1a and Table 1). Only one of the 12,365 samples negative by RT-qPCR was positive by RNA RT-LAMP. 588 samples were tested in duplicate and 12,031 were tested as single replicates. Of those samples tested in duplicate seven were detected by RNA RT-LAMP in only a single replicate ( $C_T$ s 27.00, 32.66, 33.14, 33.16, 34.07, 35.05, and 37.20 all of these had received at least one freeze thaw before analysis. Overall diagnostic sensitivity (DSe) was 96.06% (95% CI 92.88-98.12) and specificity (DSp) 99.99% (95% CI 99.95-100.00), which is corrected to DSe 95.98% (95% CI 92.70-97.83) and DSp 99.99% (95% CI 99.94-100.00) after site meta-analysis Diagnostic sensitivity of samples with a  $C_T \leq 25$  (n= 123) was 100.00% (95% CI 96.76-100.00) and specificity 99.99% (95% CI 99.95-100.00), and of samples with a  $C_T \leq 33$  (n=180) was 98.65% (95% CI 96.10-99.72) and specificity 99.99% (95% CI 99.95-100.00).

**Table 1.** Diagnostic sensitivity and specificity of RNA RT-LAMP on swabs compared with RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;45 Swab</b>	RNA RT-LAMP Pos	244 <sup>†</sup>	1	245	<b>DSe</b>	96.06	92.88-98.12
	RNA RT-LAMP Neg	10	12364	12374	<b>DSp</b>	99.99	99.95-100
	Total	254	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;33 Swab</b>	RNA RT-LAMP Pos	219	1	220	<b>DSe</b>	98.95	96.10-99.72
	RNA RT-LAMP Neg	3	12364	12367	<b>DSp</b>	99.9	99.95-100
	Total	222	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b>C<sub>T</sub> &lt;25 Swab</b>	RNA RT-LAMP Pos	112	1	113	<b>DSe</b>	100	96.76-100
	RNA RT-LAMP Neg	0	12364	12364	<b>DSp</b>	99.9	99.95-100
	Total	112	12365				

<sup>†</sup>Five samples included in this number were positive by RT-qPCR but did not have an associated C<sub>T</sub> value due to being assayed on a platform that did not produce a C<sub>T</sub> value. DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

### Direct RT-LAMP on naso/oropharyngeal swabs

559 swab samples were assayed by Direct RT-LAMP of which 199 were RT-qPCR positive and 360 were RT-qPCR negative. Direct RT-LAMP detected 140 of the 199 samples positive by RT-qPCR (Figure 1b and Table 2). 195 samples were tested in duplicate and 364 tested as single replicates. Seven of 195 samples tested in duplicate were positive by Direct RT-LAMP in only one replicate ( $C_T$  27.51, 27.95, 28.15, 28.15, 28.87, 28.92, and 28.95) all these samples had received at least one freeze thaw before analysis. Overall diagnostic sensitivity was 70.35% (95% CI 63.48-76.60) and specificity 100% (95% CI 98.98-100). After correction by site meta-analysis, the DSe is corrected to 67.59% (95% CI 53.71-78.94). Diagnostic sensitivity of samples with a  $C_T \leq 25$  ( $n=113$ ) was 100% (95% CI 96.34-100) and specificity 100% (95% CI 98.98-100), and of samples with a  $C_T \leq 33$  ( $n=182$ ) was 77.78% (95% CI 70.99-83.62) and specificity 100% (95% CI 98.98-100).

**Table 2.** Diagnostic sensitivity and specificity of Direct RT-LAMP on swabs compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 45</math> Swab</b>	Direct RT-LAMP Pos	140	0	140	<b>DSe</b> 70.35	63.48-76.60
	Direct RT-LAMP Neg	59	360	419	<b>DSp</b> 100	98.98-100
	Total	199	360			
		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 33</math> Swab</b>	Direct RT-LAMP Pos	140	0	140	<b>DSe</b> 77.78	70.99-83.62
	Direct RT-LAMP Neg	40	360	400	<b>DSp</b> 100	98.98-100
	Total	180	360			
		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 25</math> Swab</b>	Direct RT-LAMP Pos	99	0	99	<b>DSe</b> 100	96.34-100
	Direct RT-LAMP Neg	0	360	360	<b>DSp</b> 100	98.98-100
	Total	99	360			

DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

### RNA RT-LAMP on saliva

Saliva samples numbering 12,521 were assayed by RNA RT-LAMP of which 155 were RT-qPCR positive and 12,366 were RT-qPCR negative. RNA RT-LAMP detected 133 of the 155 samples that were positive by RT-qPCR (Figure 1c and Table 3). Only one of the 12,366 samples negative by RT-qPCR was positive by RNA RT-LAMP. 44 samples were tested in duplicate and 12,477 were tested as single replicates. All samples tested in duplicate were positive in both replicates. Overall diagnostic sensitivity was 80.65% (95% CI 73.54-86.54) and specificity 99.99% (95% CI 99.95-100), which is corrected to DSe 79.05% (95% CI 68.87 – 86.55) and DSp 99.99% (95% CI 99.74-100) after site meta-analysis. Diagnostic sensitivity of samples with a  $C_T \leq 25$  (n= 74) was 100% (95% CI 93.73-100) and specificity 99.99% (95% CI 99.95-100), and of samples with a  $C_T \leq 33$  (n= 150) was 87.32% (95% CI 80.71-92.31) and specificity 99.95 (95% CI 99.95-100.00).

**Table 3.** Diagnostic sensitivity and specificity of RNA RT-LAMP on saliva compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 45</math> Saliva</b>	RNA RT-LAMP Pos	125	1	126	<b>DSe</b>	80.65	73.54-86.54
	RNA RT-LAMP Neg	30	12365	12395	<b>DSp</b>	99.99	99.95-100
	Total	155	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 33</math> Saliva</b>	RNA RT-LAMP Pos	124	1	125	<b>DSe</b>	87.32	80.71-92.31
	RNA RT-LAMP Neg	18	12365	12383	<b>DSp</b>	99.99	99.95-100
	Total	142	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 25</math> Saliva</b>	RNA RT-LAMP Pos	57	1	58	<b>DSe</b>	100	93.73-100
	RNA RT-LAMP Neg	0	12365	12365	<b>DSp</b>	99.99	99.95-100
	Total	57	12366				

DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

### Direct RT-LAMP on saliva


86,760 saliva samples were tested by Direct RT-LAMP of which 247 were RT-qPCR positive and 7,195 were RT-qPCR negative (79,318 were negative on RT-LAMP but were not tested by RT-qPCR) (Figure 4d and Table 4). Direct RT-LAMP detected 209 of the 247 samples positive by RT-qPCR. 83 samples were tested in duplicate and 86,677 were tested as single replicates. Nine of the 83 samples tested in duplicate were negative in one of the duplicates and all these samples had received at least one freeze thaw before analysis ( $C_T$  20.27, 21.28, 22.01, 24.42, 25.85, 27.35, 28.52, and 30.37). Overall diagnostic sensitivity was 84.62% (95% CI 79.50-88.88) and specificity 100% (95% CI 99.72-100). After correction by site meta-analysis, DSe is corrected to 84.24% (95% CI 55.03-95.89). Diagnostic specificity was calculated using only the confirmed RT-qPCR negative samples. Diagnostic sensitivity of samples with a  $C_T \leq 25$  ( $n=126$ ) was 99.01% (95% CI 94.61-99.97) and specificity 100.00% (95% CI 99.72-100), and of samples with a  $C_T \leq 33$  ( $n=237$ ) was 87.61% (95% CI 82.69-91.54) and specificity 100% (95% CI 99.72-100).

**Table 4.** Diagnostic sensitivity and specificity of Direct RT-LAMP on saliva compared to RT-qPCR.

		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 45</math> Saliva</b>	Direct RT-LAMP Pos	209	0	209	<b>DSe</b> 84.62	79.50-88.88
	Direct RT-LAMP Neg	38	7195*	7233	<b>DSp</b> 100.00	99.95-100.00
	Total	247	7195			
		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 33</math> Saliva</b>	Direct RT-LAMP Pos	205	0	205	<b>DSe</b> 87.61	82.69-91.54
	Direct RT-LAMP Neg	29	7195*	7224	<b>DSp</b> 100.0	99.95-100.00
	Total	234	7195			
		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 25</math> Saliva</b>	Direct RT-LAMP Pos	100	0	100	<b>DSe</b> 99.01	94.61-99.97
	Direct RT-LAMP Neg	1	7195*	7196	<b>DSp</b> 100.0	99.95-100.00
	Total	101	7195			

\*85,177 samples were negative on RT-LAMP but only 7,196 were confirmed negative by RT-qPCR. Only those which were confirmed negative by RT-qPCR were included in the calculations.

### Relationship between cycle threshold ( $C_T$ ) value and time to positivity ( $T_p$ )



**Figure 1a-d:** RT-LAMP on swabs (a: RNA RT-LAMP; b: Direct RT-LAMP) and saliva (c: RNA RT-LAMP; d: Direct RT-LAMP). Time to positivity [ $T_p$ ] in minutes plotted against RT-qPCR Cycle Threshold [ $C_T$ ]. Samples which were negative by RT-qPCR are not shown. Samples which were negative by RT-LAMP are shown with 0 time to positivity. Results of linear ordinary least squared regression are shown for samples which were RT-LAMP positive with corresponding 95% confidence interval.

The relationship between  $C_T$  value and  $T_p$  was explored with the results shown in Figure 1. Whilst there is a weak linear relationship between  $C_T$  value and  $T_p$  across all methods and sample types, a stronger linear relationship was observed in swab samples with  $T_p = 0.340C_T + 0.502$  for RNA RT-LAMP and  $T_p = 0.423C_T - 0.407$  for Direct RT-LAMP. There was a notably weaker linear relationship in saliva samples for RNA RT-LAMP and  $T_p = 0.298C_T + 1.889$  for Direct RT-LAMP. For RNA RT-LAMP, there was a



notable increase in  $T_p$  variance,  $\sigma_{T_p}^2$ , after  $C_T=20$  across both sample types. On saliva samples,  $\sigma_{T_p}^2 = 0.81$  for  $C_T \leq 20$ , and  $\sigma_{T_p}^2 = 20.41$  for  $C_T > 20$ ; on swabs samples,  $\sigma_{T_p}^2 = 1.96$  and  $C_T \leq 20$ , and  $\sigma_{T_p}^2 = 15.72$  for  $C_T > 20$ .

## Individual time course

In the time course experiment SARS-CoV-2 RNA was detected from day 5 (at the onset of symptoms) up to day 12 post suspected initial exposure using Direct RT-LAMP and up to day 13 by RNA RT-LAMP, encompassing the full six days where symptoms were recorded (Table 5).

**Table 5.** RT-LAMP results of time course from symptom onset

Days post suspected exposure	Direct RT-LAMP			RNA RT-LAMP			RT-qPCR C <sub>T</sub>		Observed Symptoms
	Tp 1	Tp 2	Result	Tp 1	Tp 2	Result	ORF1ab	N	
5	09:18	09:32	POS	11:09	10:50	POS	23.31	26.47	Onset: Sore throat. Blocked nose. Headache. Lack of appetite. Fever.
6	10:32	11:34	POS	10:34	10:40	POS	21.16	24.03	Sore throat. Headache. Restless sleeping. Tired
7	10:19	13:40	POS	11:39	09:59	POS	24.47	27.30	Headache. Restless sleeping. Tired. Loss of smell and taste.
9	09:31	09:14	POS	08:35	09:37	POS	28.55	31.89	Tired. Loss of smell and taste.
11	13:14	11:47	POS	16:44	16:39	POS	26.44	29.06	Tired. Loss of smell and taste.
12	09:10	10:09	POS	12:42	12:01	POS	26.13	29.19	Tired. Improvement in smell and taste.
13	NEG	NEG	NEG	14:06	12:56	POS	28.16	30.62	Significant improvement in all symptoms
14	NEG	NEG	NEG	NEG	NEG	NEG	38.05	40.73	None
16	NEG	NEG	NEG	NEG	NEG	NEG	36.11	NEG	None
17	NEG	NEG	NEG	NEG	NEG	NEG	NEG	NEG	None

Time to positivity in minutes [Tp]; Cycle Threshold [C<sub>T</sub>]; Negative [NEG]; positive [POS]


### SARS-CoV-2 viral culture of clinical samples across a C<sub>T</sub> range

Table 6: Viral culture of positive VTM from oro/pharyngeal swabs and assay results


Sample	Original TP/C <sub>T</sub> provided pre-storage	Direct RT-LAMP	RNA RT-LAMP	Genesig RDRP gene	C <sub>T</sub> values		cpe	Decrease in C <sub>T</sub> from P0 D0 to P0 D7	C <sub>T</sub> decrease D0 to D7	
					VIASURE	SARS-CoV E gene Sarbeco assay			P1	P2
1	22.3	POS	POS	19.9	18.7	17.8	+ P2¶	+	n/a	n/a
2	21.6	POS	POS	21.3	19.9	19.0	+	+	n/a	n/a
3	25.8	POS	POS	21.6	19.1	18.5	+	+	n/a	n/a
4	TP: 5:00	POS	POS	22.6	20.8	19.8	+	+	n/a	n/a
5	24.8	POS	POS	22.9	21.6	21.0	+	+	n/a	n/a
6	24.8	POS	POS	23.7	20.6	20.6	+	+	n/a	n/a
7	22.0	NEG*	POS	24.3	21.4	20.4	+	+	n/a	n/a
8	23.0	NEG*	POS	25.3	22.0	21.3	No cpe	n/a	n/a	n/a
9	TP: 6:42	NEG*	POS	26.0	23.7	23.0	+	+	n/a	n/a
10	TP: 10:00	NEG*	NEG	36.1	31.5	32.7	No cpe	n/a	n/a	n/a
11	34.6	NEG	POS	U			No cpe	No	No	No
12	34.5	NEG	POS	39.2			No cpe	No	No	No
13	34.4	NEG	POS	35.2			No cpe	No	No	No
14	34.2	NEG	NEG	34.6			No cpe	No	No	No
15	34.2	NEG	POS	35.4			No cpe	No	No	No
16	33.4	NEG	POS	36.2			No cpe	No	No	No
17	32.6	POS	POS	35.8			No cpe	No	No	No
18	32.4	POS	POS	34.5			No cpe	No	No	No
19	31.1	NEG	POS	35.1			No cpe	No	No	No
20	30.7	POS	POS	30.0			No cpe	No	No	No
21	29.9	POS	POS	32.3			No cpe	No	No	No
22	29.7	NEG	POS	34.6			No cpe	No	No	No
23	29.6	POS	POS	31.3			No cpe	No	No	No
24	29.5	NEG	POS	30.3			No cpe	No	No	No
25	28.9	NEG	POS	30.0			No cpe	No	No	No
26	28.5	NEG	POS	31.5			No cpe	No	No	No
27	28.3	NEG	POS	30.7			+	No	No	No
28	28.1	POS	POS	29.9			No cpe	No	No	No
29	26.0	POS	POS	29.4			No cpe	No	No	No
30	23.5	NEG* <sup>2</sup>	POS	28.2			+	yes	No	No

Original sample result was generated from Genesig RDRP assay at time of diagnosis. \*Previously un-optimised method without lysis buffer. \*2 – precipitate observed in lysis mix.

Although not a large sample size; a negative result via Direct RT-LAMP does seem indicate the presence of culturable virus is less probable and recoverable virus C<sub>T</sub> >25 for RDRP/ORF1ab target is less likely. The sensitivity of the viral culture assay is presented in Supplementary data 2 of 1 pfu/ml.



Performance of RT-LAMP across viral load groups



**Figure 2:** Performance of the RNA RT-LAMP and Direct RT-LAMP assays on both saliva and swab samples according to viral load groupings.

The sensitivity of the RNA and Direct RT-LAMP assays across viral load groups is shown in Figure 2. For RNA RT-LAMP, samples which were positive by RT-qPCR containing  $>10^5$  copies/ml were consistently identified as positive with no samples returning a negative result. Below this copy number, sensitivity is reduced for both saliva and swab samples, reaching ~60% in swab samples exclusively with viral loads  $<10^3$  copies/ml, and an approximately linear drop in sensitivity from 100% to 0% between viral loads of  $10^5$  and  $10^3$  copies/ml respectively in saliva samples. For Direct RT-LAMP, all but one saliva sample were detected above  $10^6$  copies/ml. On swab samples, sensitivity is reduced on samples containing below  $<10^5$  copies/ml, dropping from 85% at viral loads of  $10^5$ – $10^6$  copies/ml, to 30% in the  $10^4$ – $10^5$  range. On saliva samples, sensitivity is reduced in the  $10^4$ – $10^5$  range to a sensitivity of 80% but then reduces further within the  $10^3$ – $10^4$  range, to 30%.

Site meta-analysis




Figure 3: Forest plots for each method and sample type showing site heterogeneity in sensitivity and specificity, with overall estimates and the resulting expected sensitivity and specificity retrieved from each respective bivariate random effects model.

Site-level confusion matrices, sensitivity, and specificity per method and sample type in Figure 3. Heterogeneity between sites for the specificity was minimal for all combinations of method and sample type, with the random effects model matching the overall aggregated sample calculation. For sensitivity, heterogeneity was minimal between sites for RNA RT-LAMP. However, for Direct RT-LAMP, sensitivity showed significant overall heterogeneity (bivariate model variance:  $\sigma_{s_e}^2 = 1.817$  on saliva samples;  $\sigma_{s_e}^2 = 0.228$  on swab samples). Between-site variations in the viral load of the samples tested contributed a minority of the heterogeneity, but sensitivity was consistently high in samples with higher viral loads (i.e.,  $>10^6$  copies/ml, as shown in Figure 2), while being more heterogeneous between sites in samples with lower viral loads. Sensitivity at lower viral loads was highest in the sites with the most established testing programmes.



## Discussion

Testing of human populations for SARS-CoV-2 nucleic acid has been hampered by both logistical (e.g., swab availability) and physical (e.g., discomfort from repeat swab testing) constraints. The aim of this study was to evaluate an optimised sample preparation method, building upon previously published methods for the extraction-free detection of SARS-CoV-2 by RT-LAMP primarily from saliva<sup>4,11</sup>. Collection of saliva is non-invasive and does not require a trained individual or specialist consumables for collection of a quality sample. Utilising a non-invasive sampling method should open testing to more individuals who dislike or are unable to tolerate having a nasopharyngeal/oropharyngeal swab taken. The salivary glands are reported to be early targets of SARS-CoV-2 infection<sup>16,17</sup>, and studies have demonstrated the detection of high viral loads of SARS-CoV-2 from saliva, similar to those observed from nasopharyngeal/oropharyngeal swabs<sup>5,7,18,19</sup>. Additionally, several studies have demonstrated that SARS-CoV-2 viral RNA could be detected from saliva for a similar duration post onset of clinical signs when compared to combined naso/oropharyngeal swabs<sup>20-22</sup>, highlighting saliva as a valuable tool for SARS-CoV-2 detection.

Direct detection negates the requirement for RNA extraction<sup>23,24</sup>, for which there has previously been competition for reagents and often requires expensive extraction equipment including liquid handling automation. This extraction-free method decreases turnaround time from sample collection to result. The Direct RT-LAMP method is straight forward and rapid, allowing the test to be performed in a wide range of settings, including near-patient hospital laboratories and pop-up or mobile laboratories. However, previously evaluated extraction-free sample preparation methods using RT-LAMP from saliva samples have demonstrated reduced sensitivity<sup>4,11</sup>, likely due to the inhibitory factors found within saliva that may affect molecular tests such as RT-LAMP and RT-qPCR<sup>25,26</sup>. The simple sample preparation method evaluated in the study aimed to improve upon these methods by utilising the addition of a novel proprietary reagent, RapiLyze<sup>®</sup>, designed to neutralize common sample inhibitors. A subsequent heat step of 98°C for two minutes prior to addition to the RT-LAMP master mix renders SARS-CoV-2 inactive as confirmed by infectivity analysis using live virus inactivation studies (See supplementary 2). Downstream steps are then able to proceed outside of traditional containment level laboratory settings broadening its clinical utility.

Our study utilised high numbers of combined naso/oropharyngeal swabs (n= 559) and saliva samples (n = 86,760) for the evaluation of this novel sample preparation method in combination with the Direct RT-LAMP assay. RNA RT-LAMP was also performed on >25,000 samples for comparison, providing updated values for the performance of the assay reported previously<sup>4,11,27</sup>. Correlation between C<sub>T</sub> value and sample viral copy number has been demonstrated within this and other

studies, with lower  $C_T$  values ( $C_T < 25$  and  $< 33$ ) indicating a higher probability that the sample contains recoverable active virus, and consequently the likelihood that the individual may be infectious to others<sup>4,25,28-31</sup>. As a result, the RNA and Direct RT-LAMP assays were compared with RT-qPCR results in groups with three different  $C_T$  cut-off values:  $<45$ ,  $<33$  and  $<25$ . This was completed so that the performance of the assays in different clinical scenarios (use case) could be determined: (i)  $C_T <45$ : does the RT-LAMP assay (either RNA or Direct) compare with RT-qPCR for all reportable  $C_T$  values?; (ii)  $C_T <33$ : can the RT-LAMP assay detect those individuals that have a medium-high levels of viral RNA in their specimens, with an ORF1ab target being analogous with viral copy number because it is exclusively a genomic target<sup>14</sup>; and (iii)  $C_T <25$ : can the RT-LAMP assay detect those individuals that have a high level of viral RNA in their specimens?

In our study, diagnostic sensitivity for RNA RT-LAMP on swab and saliva samples was improved when compared to a previous report utilising this method (Fowler *et al.*, 2020), with values of  $>96\%$  and  $>80\%$ , respectively when considering all  $C_T$  values, and  $100\%$  for both sample types when considering  $C_T <25$  with these samples having a high probability of containing replicating virus for over 24,000 samples tested. Direct RT-LAMP sensitivity on swab samples was also improved from the previous method with  $100\%$  sensitivity for  $C_T <25$ ,  $77.78\%$  for  $C_T <33$  and  $70.35\%$  for  $C_T <45$  across 559 samples used for this evaluation. In contrast, sensitivity for Direct RT-LAMP on saliva was in general higher than that determined for swabs ( $C_T <33 = 87.61\%$ ,  $C_T <45 = 84.62\%$ ), apart from the group with  $C_T$  values below  $<25$ , which had a reported sensitivity of  $99.01\%$ . These results support previous reports which demonstrate comparable performance when comparing paired swabs and saliva samples<sup>32,33</sup>, and that one sample type is not superior to the other. Interestingly, the diagnostic sensitivity for RNA and Direct RT-LAMP for saliva samples was almost equivalent ( $80.65\%$  and  $84.62\%$ , respectively) suggesting that RNA extraction may not even be required when performing testing on saliva samples.

Previous studies have described the importance of identifying asymptomatic individuals, particularly those with high viral loads<sup>34-37</sup>. The ability of the Direct RT-LAMP assay to reliably detect individuals with medium-high viral loads in a simple to collect, non-invasive sampling process highlights the suitability of this assay for both symptomatic and asymptomatic population screening. This is particularly important in healthcare and care home staff where the use of asymptomatic COVID-19 screening would reduce the risk of onward transmission of SARS-CoV-2, consequently maintaining NHS capacity and Social Care capacity and more importantly, reducing the risk to vulnerable individuals present within those environments<sup>27</sup>.

It is important to note that when designing surveillance strategies for asymptomatic infection testing as an intervention to reduce transmission, frequency of testing and result turnaround time may be considered more significant than diagnostic sensitivity<sup>38</sup>. 'Gold standard' tests with high sensitivity such as RT-qPCR generally need to be performed in centralised testing facilities, often resulting in increased reporting times, leading to a less effective control of viral transmission<sup>38</sup>. In contrast, point of care tests such as Lateral flow tests (LFT)<sup>39</sup> or those requiring only a basic/mobile laboratory set-up such as Direct RT-LAMP, which have the ability to produce rapid results, can be performed frequently e.g., daily or multiple times per week. Consequently, the likelihood of sampling an individual when their viral load is highest as seen in the early, often pre-symptomatic stages of infection increases, maximising the probability of rapidly detecting infectious cases, allowing prompt isolation. In this use case sampling and testing frequency using a rapid assay with suitable accuracy in detection of medium-high viral loads, but not necessarily optimal sensitivity over the whole range including low to very low viral loads, is desirable or necessary<sup>38,40</sup>. Frequent on-site testing of asymptomatic NHS healthcare workers using Direct RT-LAMP has been successfully implemented in the pilot study described here; and continues to be utilised. Direct-RT-LAMP has also been used in a mass community based pilot in school and higher education settings<sup>27</sup>, to identify those individuals who may have been missed when surveillance relies only on symptomatic individuals coming forward for testing. With the use of mobile or pop-up laboratories, Direct RT-LAMP could also be used for risk-based mass testing, for example, targeting specific geographical areas or vulnerable groups. The potential also exists for lyophilisation of the Direct RT-LAMP reagents reported in other studies<sup>41,42</sup>, which would minimise the necessity for trained personnel by reducing pipetting steps and the requirement for a cold chain, allowing greater capacity of the assay in multi-use case scenarios including point-of-care and in low- and middle-income countries (LMICs).

Several experiments typical of a diagnostic performance evaluation were not performed as part of this study, as they had been performed and reported previously. This included both analytical specificity, which when tested against a panel of respiratory pathogens causing indistinguishable clinical signs to COVID-19, demonstrated a high level of analytical specificity (100% in this case)<sup>4</sup> and analytical sensitivity of the Direct RT-LAMP, which is reported to detect 1000 cp/ml<sup>4,27,32</sup>. Additionally, the RNA and Direct RT-LAMP assays evaluated as part of this study have been shown to reliably detect the emerging variants of concern (VOC) including the B.1.1.7 alpha variant, the 501Y.V2 beta variant, the P1 gamma variant and the new rapidly spreading B.1.617.2 delta variant<sup>43-45</sup>. The emergence of further VOC could lead to a criticism of the RT-LAMP assay due its reliance on a single target, ORF1ab, where mutations in the target region in a sample could lead to false negatives. For RT-qPCR this has been observed during the current pandemic<sup>46-48</sup> where at least a dual target

assay is recommended<sup>49</sup>. However, this is less likely to occur for the RT-LAMP assay used in this pilot evaluation. Firstly, due to the multiple sets of primer pairs utilised, 3 pairs with two pairs within the target region. This builds in redundancy to mutation not unlike a duplex RT-qPCR. Secondly, the ORF1ab region is highly conserved and crucial for viral replication and fitness in SARS-CoV-2. As a result, these regions are well maintained using a proofreading system via the nsp14 protein<sup>50</sup> resulting in a more stable genome compared to many other RNA viruses.

The authors highlight the importance of incorporating an inhibition control into the next iteration of the RT-LAMP assays. Although, the paired RT-LAMP and RT-qPCR data from this study show a good correlation and any false negative results were likely due to the analytical sensitivity of the RT-LAMP assay, not sample driven inhibition. To this end, a control primer set by OptiGene Ltd was evaluated (PS-0010), targeting the human ribosomal protein LO gene. Preliminary analysis of the inhibition control primers showed consistent detection across 279 saliva and 381 combined naso/oropharyngeal swab samples using both RNA and Direct RT-LAMP (Supplement 1). Incorporation of this inhibition control into the RT-LAMP assays would alleviate a potential limitation of the current assays and further support quality assurance for use within a clinical diagnostic setting.

This study demonstrated high sensitivity and specificity for a novel sample preparation method used for SARS-CoV-2 Direct RT-LAMP, particularly in samples from which the individual would likely be considered infectious, highlighting the usefulness of saliva as a simple to collect, non-invasive sample type. The highly sensitive RNA RT-LAMP assay provides a rapid alternative with a reliance on differing reagents and equipment to RT-qPCR testing, thus providing additional diagnostic capacity and redundancy through diversity. Direct RT-LAMP may complement existing surveillance tools for SARS-CoV-2 testing including other point-of-care and laboratory-based diagnostics and is applicable to a variety of clinical scenarios, such as frequent, interval-based testing of asymptomatic individuals that may be missed when reliance is on symptomatic testing alone. However, care should be taken when considering frequency of testing, messaging around the role and interpretation of asymptomatic rapid tests, integration of data storage and access, and the challenges faced when scaling up surveillance to large populations.

The role out of a new testing strategy can often throw up interesting and unexpected experiences. These collective experiences and lessons learnt from setting up an NHS asymptomatic staff testing programme using Direct RT-LAMP will be shared in a future publication.

## Funding

This work was partially funded by a Department of Health and Social Care award to the University of Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva based LAMP testing)). The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care. KMG is supported by the UK Medical Research Council 317 (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British Heart Foundation (RG/15/17/3174). For part of this project, Emma Howson was on secondment at GeneSys Biotech Ltd., which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA) under BBSRC grant BB/S507945/1. ADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (C31641/A23923) and his laboratory is supported by CRUK Centre Birmingham (C17422/A25154) and the Birmingham Experimental Cancer Medicine Centre (C11497/A25127). Veronica Fowler, Stephen Kidd, Bryony Armson and Zandra Deans were on secondment to the Department of Health and Social Care for a period during this study. APHA laboratory activities and expertise was supported by both the Safe and Certain project APHACSKL0085 and Defra project APHANSOM0416.

## References

- 1 Zhang Jin jin, Dong Xiang, Cao Yi yuan, Yuan Ya dong, Yang Yi bin, Yan You qin, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy Eur J Allergy Clin Immunol* 2020;**75**(7):1730–41. Doi: 10.1111/all.14238.
- 2 Johns Hopkins Coronavirus Resource Centre. Available at <https://coronavirus.jhu.edu/>. Accessed April 19, 2021, n.d.
- 3 Corman Victor M., Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel K.W., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 2020;**25**(3):23–30. Doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
- 4 Fowler Veronica L., Armson Bryony, Gonzales Jose L., Wise Emma L., Howson Emma L.A., Vincent-Mistiaen Zoe, et al. A highly effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 infection. *J Infect* 2020;**82**(1):117–25. Doi: 10.1016/j.jinf.2020.10.039.
- 5 Zhu Jialou, Guo Jiubiao, Xu Yuzhong, Chen Xinchun. Viral dynamics of SARS-CoV-2 in saliva from infected patients. *J Infect* 2020;**81**(3):e48–50. Doi: 10.1016/j.jinf.2020.06.059.
- 6 Ott Isabel M, Strine Madison S, Watkins Anne E, Boot Maikel, Kalinich Chaney C, Harden Christina A, et al. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices. *MedRxiv Prepr Serv Heal Sci* 2020. Doi: 10.1101/2020.08.03.20165233.
- 7 Azzi Lorenzo, Baj Andreina, Alberio Tiziana, Lualdi Marta, Veronesi Giovanni, Carcano Giulio, et al. Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. *J Clean Prod* 2020;**81**. Doi: 10.1016/j.jinf.2020.06.042.
- 8 Wei Shan, Suryawanshi Hemant, Djandji Alexandre, Kohl Esther, Morgan Stephanie, Hod Eldad A, et al. Field-deployable, rapid diagnostic testing of saliva for SARS-CoV-2. *Sci Rep* 2021:5448. Doi: 10.1038/s41598-021-84792-8.
- 9 Sri Santosh Tatikonda, Parmar Reshu, Anand Hanish, Srikanth Konkati, Saritha Madham. A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus* 2020;**12**(4). Doi: 10.7759/cureus.7708.
- 10 Beaumont Anne-lise, Raillon Laure-anne, Ader Florence, Chatenoud Lucienne, Hueso Thomas. Evaluation of different sample treatments options in a simple and safe procedure for the detection of SARS-COV-2 in saliva 2020;(January).
- 11 Howson Emma L.A., Kidd Stephen P., Armson Bryony, Goring Alice, Sawyer Jason, Cassar Claire, et al. Preliminary optimisation of a simplified sample preparation method to permit direct detection of SARS-CoV-2 within saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP). *J Virol Methods* 2021;**289**. Doi: <https://doi.org/10.1016/j.jviromet.2020.114048>.
- 12 Reitsma Johannes B., Glas Afina S., Rutjes Anne W.S., Scholten Rob J.P.M., Bossuyt Patrick M., Zwinderman Aeilko H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol* 2005;**58**(10):982–90. Doi: 10.1016/j.jclinepi.2005.02.022.
- 13 Bhargava Alok. Dynamic aspects of ORF1ab and N RNA cycle threshold values among COVID-19 patients in China. *Infect Genet Evol* 2021;**87**:104657. Doi: <https://doi.org/10.1016/j.meegid.2020.104657>.

- 14 Alexandersen Soren, Chamings Anthony, Bhatta Tarka Raj. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. *Nat Commun* 2020;**11**(1):6059. Doi: 10.1038/s41467-020-19883-7.
- 15 Xu Tianmin, Chen Cong, Zhu Zhen, Cui Manman, Chen Chunhua, Dai Hong, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis* 2020;**94**:68–71. Doi: 10.1016/j.ijid.2020.03.022.
- 16 Liu L., Wei Q., Alvarez X., Wang H., Du Y., Zhu H., et al. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques. *J Virol* 2011;**85**(8):4025–30. Doi: 10.1128/jvi.02292-10.
- 17 Huang Ni, Pérez Paola, Kato Takafumi, Mikami Yu, Okuda Kenichi, Gilmore Rodney C, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med* 2021. Doi: 10.1038/s41591-021-01296-8.
- 18 To Kelvin Kai Wang, Tsang Owen Tak Yin, Leung Wai Shing, Tam Anthony Raymond, Wu Tak Chiu, Lung David Christopher, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020;**20**(5):565–74. Doi: 10.1016/S1473-3099(20)30196-1.
- 19 Tan Steph H, Allicock Orchid, Armstrong-Hough Mari, Wyllie Anne L. Saliva as a gold-standard sample for SARS-CoV-2 detection. *Lancet Respir Med* 2021;**2600**(21):19–21. Doi: 10.1016/S2213-2600(21)00178-8.
- 20 Uwamino Yoshifumi, Nagata Mika, Aoki Wataru, Fujimori Yuta, Nakagawa Terumichi, Yokota Hiromitsu, et al. Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. *J Clin Pathol* 2021;**74**(1):67–8. Doi: 10.1136/jclinpath-2020-206972.
- 21 Wyllie Anne L., Fournier John, Casanovas-Massana Arnau, Campbell Melissa, Tokuyama Maria, Vijayakumar Pavithra, et al. *Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2*. 2020.
- 22 Vogels Chantal B.F., Watkins Anne E., Harden Christina A., Brackney Doug E., Shafer Jared, Wang Jianhui, et al. SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity. *Med* 2020:1–18. Doi: 10.1016/j.medj.2020.12.010.
- 23 Buck Michael D., Poirier Enzo Z., Cardoso Ana, Frederico Bruno, Canton Johnathan, Barrell Sam, et al. SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. *Wellcome Open Res* 2021;**6**:9. Doi: 10.12688/wellcomeopenres.16517.1.
- 24 Kellner Max J, Matl Martin, Ross James J, Schnabl Jakob, Handler Dominik, Heinen Robert, et al. Head-to-head comparison of direct-input RT-PCR and RT-LAMP against RT-qPCR on extracted RNA for rapid SARS-CoV-2 diagnostics. *MedRxiv* 2021:2021.01.19.21250079.
- 25 Ochert A. S., Boulter A. W., Birnbaum W., Johnson N. W., Teo C. G. Inhibitory effect of salivary fluids on PCR: Potency and removal. *PCR Methods Appl* 1994;**3**(6):365–8. Doi: 10.1101/gr.3.6.365.
- 26 Wilson I. G. Inhibition and facilitation of nucleic acid amplification. *Appl Environ Microbiol* 1997;**63**(10):3741–51. Doi: 0099-2240/97/\$04.00?0.
- 27 DHSC. Rapid evaluation of OptiGene RT-LAMP assay (direct and RNA formats). Department of Health and Social Care. United Kingdom. 2020.

- 28 La Scola Bernard, Le Bideau Marion, Andreani Julien, Hoang Van Thuan, Grimaldier Clio, Colson Philippe, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 2020;**39**(6):1059–61. Doi: 10.1007/s10096-020-03913-9.
- 29 Bullard Jared, Dust Kerry, Funk Duane, Strong James E, Alexander David, Garnett Lauren, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. *Clin Infect Dis* 2020;**71**(10):2663–6. Doi: 10.1093/cid/ciaa638.
- 30 Wölfel Roman, Corman Victor M., Guggemos Wolfgang, Seilmaier Michael, Zange Sabine, Müller Marcel A., et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;**581**(7809):465–9. Doi: 10.1038/s41586-020-2196-x.
- 31 Marc Aurélien, Keroui Marion, Blanquart François, Bertrand Julie, Mitjà Oriol, Corbacho-Monné Marc, et al. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. *MedRxiv* 2021:2021.05.07.21256341.
- 32 Fowler Veronica L., Douglas Angela, Godfrey Keith M., Williams Anthony, Beggs Andrew, Kidd Stephen P., et al. Critical evaluation of the methodology used by Wilson-Davies et al., (2020) entitled “Concerning the Optigene Direct LAMP assay, and its use in at-risk groups and hospital staff.” *J Infect* 2021. Doi: <https://doi.org/10.1016/j.jinf.2021.01.012>.
- 33 Hanson Kimberly E., Barker A. P., Hillyard D. R., Gilmore N., Barrett J. W., Orlandi R. R., et al. Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. *J Clin Microbiol* 2020;(July):1–5. Doi: 10.1101/2020.07.17.20155754.
- 34 Nikolai Lea A, Meyer Christian G, Kreamsner Peter G, Velavan Thirumalaisamy P. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information 2020;(January).
- 35 Marks Michael, Millat Pere, Ouchi Dan, Roberts Chrissy, Alemany Andrea, Corbacho-Monné Marc, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: A cohort study. *MedRxiv* 2020;**3099**(20):1–8. Doi: 10.1101/2020.10.27.20220277.
- 36 Byambasuren Oyungerel, Cardona Magnolia, Bell Katy, Clark Justin, McLaws Mary Louise, Glasziou Paul. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. *J Assoc Med Microbiol Infect Dis Canada* 2020;**5**(4):223–34. Doi: 10.3138/jammi-2020-0030.
- 37 Buitrago-Garcia Diana, Egli-Gany Dianne, Counotte Michel J., Hossmann Stefanie, Imeri Hira, Ipekci Aziz Mert, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic review and meta-analysis. *PLoS Med* 2020;**17**(9):1–25. Doi: 10.1371/journal.pmed.1003346.
- 38 Larremore Daniel B., Wilder Bryan, Lester Evan, Shehata Soraya, Burke James M., Hay James A., et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv* 2021;**7**(1):1–11. Doi: 10.1126/sciadv.abd5393.
- 39 Lee Lennard Y W, Rozmanowski Stefan, Pang Matthew, Charlett Andre, Anderson Charlotte, Hughes Gareth J, et al. An observational study of SARS-CoV-2 infectivity by viral load and demographic factors and the utility lateral flow devices to prevent transmission. *Preprint* n.d.
- 40 Kissler S.M., Fauver J.R., Mack C., Tai C., Shiue K.Y., Kalinich C.C., et al. Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing. *MedRxiv* 2020:1–13.



- 41 Howson E.L.A., Armson B., Madi M., Kasanga C. J., Kandusi S., Sallu R., et al. Evaluation of Two Lyophilized Molecular Assays to Rapidly Detect Foot-and-Mouth Disease Virus Directly from Clinical Samples in Field Settings. *Transbound Emerg Dis* 2017;**64**(3):861–71. Doi: 10.1111/tbed.12451.
- 42 Armson Bryony, Walsh Charlotte, Morant Nick, Fowler Veronica L, Knowles Nick J., Clark Duncan. The development of two field-ready reverse transcription loop-mediated isothermal amplification assays for the rapid detection of Seneca Valley virus 1. *Transbound Emerg Dis* 2019;**66**(1):497–504. Doi: 10.1111/tbed.13051.
- 43 Horby Peter, Huntley Catherine, Davies Nick, Edmunds John, Ferguson Neil, Medley Graham, et al. NERVTAG note on B.1.1.7 severity. 2021.
- 44 Tegally Houriiyah, Wilkinson Eduan, Giovanetti Marta, Iranzadeh Arash, Fonseca Vagner, Giandhari Jennifer, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *MedRxiv* 2020;**2**. Doi: 10.1101/2020.12.21.20248640.
- 45 Public Health England. COVID-19 (SARS-CoV-2) variants. 11/06/2021. Available at <https://www.gov.uk/government/collections/new-sars-cov-2-variant>. Accessed June 17, 2021, n.d.
- 46 Vanaerschot Manu, Mann Sabrina A, Webber James T, Kamm Jack, Bell Sidney M, Bell John, et al. Identification of a Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts Detection by Reverse Transcription-PCR. *J Clin Microbiol* 2020;**59**(1):e02369-20. Doi: 10.1128/JCM.02369-20.
- 47 Hasan Mohammad Rubayet, Sundararaju Sathyavathi, Manickam Chidambaram, Mirza Faheem, Al-Hail Hamad, Lorenz Stephan, et al. A Novel Point Mutation in the N Gene of SARS-CoV-2 May Affect the Detection of the Virus by Reverse Transcription-Quantitative PCR. *J Clin Microbiol* 2021;**59**(4):e03278-20. Doi: 10.1128/JCM.03278-20.
- 48 Artesi Maria, Bontems Sébastien, Göbbels Paul, Franckh Marc, Maes Piet, Boreux Raphaël, et al. A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. *J Clin Microbiol* 2020;**58**(10):e01598-20. Doi: 10.1128/JCM.01598-20.
- 49 Wang Rui, Hozumi Yuta, Yin Changchuan, Wei Guo-Wei. Mutations on COVID-19 diagnostic targets. *Genomics* 2020;**112**(6):5204–13. Doi: <https://doi.org/10.1016/j.ygeno.2020.09.028>.
- 50 Rausch Jason W, Capoferri Adam A, Katusiime Mary Grace, Patro Sean C, Kearney Mary F. Low genetic diversity may be an Achilles heel of SARS-CoV-2. *Proc Natl Acad Sci* 2020;**117**(40):24614 LP – 24616. Doi: 10.1073/pnas.2017726117.

## Supplementary Information 1

### **Log reduction of SARS-CoV-2 for the heat and lysis steps used independently and sequentially**

We have determined the viral inactivation kinetics of the best sample preparation condition(s), evaluating the effect of the heat and lysis steps on the viral inactivation of SARS-CoV-2 as determined by infectivity assays. All inactivation experiments had to be conducted under Containment Level 3 Containment and as such was undertaken at APHA.

Heat inactivation experiments were conducted utilising high titre live SARS-CoV-2 virus spiked into pools of saliva collected from APHA staff or in tissue culture supernatant (TCSN). Early experiments demonstrated that saliva had a high toxicity for tissue culture cells, even after heat inactivation demonstrating that toxicity was likely not enzymatic. As such further inactivation was undertaken on live virus TSCN. These heat inactivation experiments demonstrated that SARS-Cov-2 was completely inactivated by heating at 60°C (20 min plus) or ≥70°C (after 2, 5 or 10 min). Importantly optimised RapiLyze Sample Lysis Buffer did not inactivate live virus. Further, inactivation at 56°C was not 100% effective at shorter incubation times, and additionally showed a loss in sensitivity following a 4 x 2-fold dilution (See table 2, P07102) at 10 and 30 minutes.

P07553 (C <sub>T</sub> 19)	1:2	1:4	1:8	1:16	1:36	1:64	1:128	1:256	1:512	1:1024	1:2048
VTM 1:1 into Lysis + 98°C	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+
56°C 10 mins pre-treat 1:1 VTM into lysis +98°C	+	+	+	+	+	+	+	+	+	+	-
	+	+	+	+	+	+	+	+	+	+	-
56°C 30 mins pre-treat 1:1 VTM into lysis +98°C	+	+	+	+	+	+	+	-	+	-	-
	+	+	+	+	+	+	+	+	-	-	-

**Table 1:** Serial dilution of Patient VTM (C<sub>T</sub>19) 1:1 VTM into Lysis Buffer and 98°C heat treatment without and without heat pre-treatment at 56°C for 10 or 30 minutes

Patient VTM	P07553 (C <sub>T</sub> 19)	P01127 (C <sub>T</sub> 23.97)	P07102 (C <sub>T</sub> 32.08)	P07392 (C <sub>T</sub> 24.55)	P01071 (C <sub>T</sub> 20.54)
VTM into 1:1 Lysis + 98 °C	+	+	+	+	+
	+	+	+	+	+
56 °C 30 mins pre-treat 1:1 VTM into lysis + 98 °C	+	+	-	+	+
	+	+	-	+	+

**Table 2:** Serial dilution of Patient VTM (C<sub>T</sub>19.00 to 32.08) 1:1 VTM into Lysis Buffer and 98°C heat treatment without and without heat pre-treatment at 56°C for 10 or 30 minutes

Interestingly, following optimisation of heat inactivation of live virus, pre-treatment of samples was assessed to determine any impact of pre-treatment on assay sensitivity. A pre-treatment 70°C for 5 mins carried out on spiked samples prior to the proposed direct RT-LAMP assay has no effect on subsequent LAMP or PCR results. Further experiments to test the effect of this pre-treatment on positive patient samples will be carried out to confirm this result. It recommended that even if a pre-treatment is effective in inactivating the virus that downstream processes are carried out in UV hoods or with effective air-flow management to prevent cross contamination of the direct RT-LAMP assay.

Comparison of Betapropiolactone (BPL) inactivated virus and live virus have demonstrated that BPL inactivation has resulted in lower sensitivity of detection using direct RT-LAMP. BPL inactivated virus is not an ideal substitute for live virus in spiking experiments. Any conclusions on assay sensitivity or performance have therefore been drawn from experiments on spiking of live virus in TCSN or saliva carried out in containment. Spiking of live virus into pooled saliva has demonstrated that direct detection by RT-LAMP is possible in samples that give a C<sub>T</sub> below 25/26 with extraction and PCR.

## **Supplementary Information 2**

### Sensitivity of the viral culture assay – 1 pfu/ml

The virus was diluted and a set number of pfu of virus (1000, 100, 10, 1 and 0.1) was added to duplicate flasks containing Vero E6 cells and also to AVL. Flasks were viewed for cpe. Supernatant from flasks that showed no cpe were passed on twice. No cpe was observed in the flasks inoculated with 0.1 or 0.01 pfu after the two passes. AVL samples were taken from the flasks at the beginning and end of each passage and the C<sub>T</sub> values of the extracted nucleic acids shown below.

Number of pfu added to AVL/flask	E Gene Rt-PCR assay			Growth (cpe)	
	Ct value of dilution (AVL)	Baseline Mean Ct value from flasks	Final Mean Ct value from flasks	Flask 1	Flask 2
1000	19.64	25.0	12.2	+	+
100	22.65	28.4	11.8	+	+
10	26.00	31.8	11.9	+	+
1	28.73	35.0	12.6	+	+
0.1	32.11	37.6	37.3	-	-
0.01	34.43	39.8	37.7	-	-